Atomo and Access Bio renegotiate supply agreements
Filed with ASX · · 2 pages · English
reflect the evolving structural changes in the COVID-19 diagnostics market. Under the new agreement, which has immediate effect and expires on 31 December 2022, Atomo will receive from Access Bio a one-off fee considered by Atomo to be material and replacing any payments due to Atomo under the existing agreements. The new agreement also provides Atomo the right, but not the obligation, to purchase
Story so far
Earlier from Atomo Diagnostics
- FY21 Results Presentation
- Appendix 4E & Annual Financial Report
- Quarterly Activity Report - 30 June 2021
- Appendix 4C - 30 June 2021
- Access Bio receives FDA clearance for COVID-19 antibody test
Later from Atomo Diagnostics
- Appendix 4C - 30 September 2021
- Quarterly Activity Report - 30 September 2021
- HIV Self-Test - improved supply & advertising conditions
- Appendix 4C - 31 December 2021
- Quarterly Activity Report - 31 December 2021
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics